Combined oxidative phosphorylation deficiency caused by mutation in MRPS16 is a very rare, serious genetic disease of the mitochondria, the “power plants” inside our cells.[1] In this disease, the main energy-making system in mitochondria, called oxidative phosphorylation, does not work properly, so the body cannot make enough energy (ATP) for normal life and growth.[1] It usually starts right after birth or in the first weeks of life. Babies may have trouble breathing, very high acid levels in the blood (lactic and metabolic acidosis), poor muscle tone, feeding problems, and serious brain changes like missing the main bridge between the two halves of the brain (agenesis of the corpus callosum).[1]
Combined oxidative phosphorylation deficiency 2 (COXPD2) is a very rare, serious mitochondrial disease. It happens when both copies of the MRPS16 gene (one from each parent) have a harmful change (mutation). This gene makes a small protein that is part of the mitochondrial ribosome, the “protein factory” inside mitochondria. When MRPS16 does not work, many mitochondrial proteins cannot be made properly, so oxidative phosphorylation (OXPHOS) – the main way cells make energy (ATP) – does not work well. This causes severe lack of energy in many organs, especially the brain, muscles, and heart. Many babies with this condition have poor growth, small head size (microcephaly), agenesis or thinning of the corpus callosum in the brain, lactic acidosis, and serious developmental delay.
Because the disease is genetic and present from birth, there is no simple cure or single “magic” medicine. Treatment focuses on careful support of breathing, feeding, movement, seizures, acid–base balance, and comfort. Research on mitochondrial diseases in general is growing, but for MRPS16-related COXPD2, evidence is limited to a few case reports and expert opinion, not large clinical trials.
The disease is autosomal recessive. This means both parents usually carry one silent copy of the changed MRPS16 gene, and the baby gets both changed copies, one from each parent.[2]
Because the energy problem is very strong and affects many body systems, especially the brain and muscles, the condition is often life-threatening in the newborn period.[1]
Other names
Doctors and science books may use many other names for the same condition:[1]
-
Combined oxidative phosphorylation deficiency 2 (COXPD2)
-
Combined oxidative phosphorylation defect type 2
-
Combined oxidative phosphorylation deficiency caused by mutation in MRPS16
-
MRPS16-related combined oxidative phosphorylation deficiency
-
Agenesis of corpus callosum with dysmorphism and fatal lactic acidosis (an older descriptive name based on brain and facial findings and severe lactic acidosis)
-
Corpus callosum, agenesis of, with dysmorphism and fatal lactic acidosis
All these names point to the same basic problem: a disease linked to changes in the MRPS16 gene that damage mitochondrial energy production.[1M
Simple explanation of mitochondria and oxidative phosphorylation
Mitochondria are tiny parts inside almost every cell. They act like small batteries or power plants. Their main job is to make ATP, the basic energy “coin” that cells use for every task, from moving muscles to sending brain signals.[1]
Inside mitochondria, several “machines” called respiratory chain complexes (I, II, III, IV, V) pass electrons and pump protons. Together they perform oxidative phosphorylation, the final step that joins oxygen and nutrients to make ATP. In this disease, several of these complexes do not work well at the same time, so it is called “combined” oxidative phosphorylation deficiency.[1]
When the respiratory chain does not work, cells switch to backup energy pathways, which produce large amounts of lactic acid. This leads to lactic acidosis and metabolic acidosis, which are dangerous for the heart, brain, and other organs, especially in newborn babies.[1]
Role of the MRPS16 gene
The MRPS16 gene gives instructions to build a protein called mitochondrial ribosomal protein S16. This protein is part of the small 28S subunit of the mitochondrial ribosome, the “protein-making machine” inside mitochondria.[1]
If MRPS16 is changed (mutated), the mitochondrial ribosome cannot make many important mitochondrial proteins correctly. These proteins are needed for the respiratory chain complexes. If they are missing or faulty, the oxidative phosphorylation system fails, and ATP production drops strongly.[1]
Studies of patients with MRPS16 mutations show strong defects in mitochondrial translation (the process of making proteins from RNA) together with reduced amounts and activities of several complexes (I, III, IV, and ATP synthase).[1]
Because the brain and muscles use large amounts of energy, they are especially sensitive to this defect. This explains the severe brain changes, poor muscle tone, and early death seen in many affected babies.[1]
Types
Doctors do not have official, widely accepted “types” for MRPS16-related combined oxidative phosphorylation deficiency, because very few patients have been reported. However, to make the pattern easier to understand, we can think about three clinical patterns. These are not strict medical subtypes, but simple ways to describe how severe the condition is and how early it appears.[1]
-
Classic neonatal lethal pattern
In this pattern, symptoms show at birth or in the first days of life. The baby has severe lactic acidosis, very weak muscle tone, serious brain malformations such as agenesis of the corpus callosum, and often cannot survive beyond the newborn period despite intensive care.[1] -
Severe early infant pattern
Here, the baby may look slightly better at birth but soon develops feeding problems, failure to gain weight, increasing lactic acidosis, seizures, breathing trouble, and marked developmental delay. Death usually occurs in early infancy.[1] -
Very rare milder or atypical pattern (theoretical)
Because only very few families are known, doctors think there may be milder or somewhat different presentations if the genetic change damages MRPS16 less strongly. These individuals might show brain white matter disease and developmental problems but survive longer. Evidence is very limited, and this pattern is mostly theoretical based on how other mitochondrial ribosomal protein disorders can behave.[1]
Non-pharmacological treatments (therapies and other supports)
These are supportive measures that do not use standard drugs but can be very important in care. Evidence is mostly from expert practice in mitochondrial disease, not from big randomized trials.
-
Multidisciplinary care team
A coordinated team (metabolic / mitochondrial specialist, neurologist, cardiologist, dietitian, physiotherapist, occupational therapist, palliative-care team) is vital. The team reviews growth, breathing, heart function, seizures, nutrition, and development, and they adjust the plan regularly. This helps catch problems early and gives families one clear plan instead of many separate opinions. -
Careful nutrition planning
Many babies with COXPD2 have poor feeding and weight gain. A metabolic dietitian can design a high-calorie, high-protein plan with frequent small feeds to avoid fasting and low blood sugar. Feeding may be by mouth, nasogastric tube, or gastrostomy tube, depending on safety and aspiration risk. The aim is steady energy supply and prevention of catabolism (breakdown of body tissues). -
Avoidance of prolonged fasting
Fasting stresses mitochondria and increases lactic acidosis. Parents are often given “sick-day rules” so that if the child is vomiting or cannot eat, they receive early glucose-containing fluids in hospital. This helps prevent metabolic crises and can reduce risk of decompensation. -
Physiotherapy and positioning
Regular physiotherapy helps prevent contractures, maintains joint range, and supports breathing by improving chest wall movement. Gentle exercises, supported sitting, and standing frames are chosen carefully to avoid over-exertion, which can worsen fatigue in mitochondrial disease. -
Occupational therapy and assistive devices
Occupational therapists can provide adapted seating, special cushions, splints, and communication aids. They also teach families how to position the child safely, protect skin, and use simple equipment at home, which can improve quality of life and prevent complications such as pressure sores and contractures. -
Speech and swallowing therapy
Speech-language therapists assess swallowing, risk of aspiration, and communication. They may recommend thickened feeds, modified textures, or tube feeding if aspiration is dangerous. They also help with early communication strategies, which is important when cognitive or motor delay is present. -
Respiratory physiotherapy and airway clearance
Children with low muscle tone may not cough well. Chest physiotherapy, suction when needed, and positioning can help clear secretions and reduce pneumonia risk. In some cases, non-invasive ventilation (like BiPAP) during sleep may support breathing. -
Developmental stimulation and early intervention
Early intervention programs use play-based therapy to stimulate vision, hearing, touch, and movement. Even if the child has severe disability, gentle interaction, toys, music, and social contact can support emotional development and family bonding. -
Infection prevention and prompt treatment
Infections increase metabolic stress and lactic acidosis. Families are taught to seek early medical help for fevers, breathing difficulty, or poor feeding. Vaccinations according to national schedules (and sometimes extra vaccines such as influenza and pneumococcal) are usually recommended. -
Avoidance of known mitochondrial-toxic drugs when possible
Some medicines (for example valproic acid, certain aminoglycoside antibiotics, and some chemotherapies) can worsen mitochondrial function. Doctors try to choose alternatives when possible, especially in children with known mitochondrial disease. Families should always tell health professionals about the diagnosis before any new drug is started. -
Palliative-care support
Because the prognosis is often poor, palliative-care teams can help families with symptom control (pain, breathlessness, seizures), decision-making, and emotional support. This does not mean “giving up”; it means focusing on comfort, dignity, and family goals alongside any disease-targeted treatments. -
Genetic counseling for the family
Parents can meet a geneticist to understand inheritance, recurrence risk in future pregnancies, and options such as carrier testing, prenatal diagnosis, or pre-implantation genetic testing. This is a key non-drug intervention because it helps families plan safely for the future.
(There are not 20 distinct evidence-based non-drug therapies specific to MRPS16-COXPD2; most centres use combinations of the supportive strategies above.)
Drug treatments
Important safety note: No drug is currently approved specifically for MRPS16-related combined oxidative phosphorylation deficiency. Most medicines below are either:
-
Standard drugs for symptoms (for example seizures) in any child, or
-
Vitamins / cofactors used off-label in mitochondrial disorders in general (“mitochondrial cocktail”), with limited evidence.
Because you asked for FDA-related information: some of these substances (for example levocarnitine, multivitamin infusions, arginine) appear in FDA labels or orphan-drug databases, but not as specific treatments for MRPS16-COXPD2.
I will list key examples (not 20), with typical uses. Exact dose and timing must always be set by a specialist.
-
Coenzyme Q10 (ubiquinone / ubiquinol)
CoQ10 carries electrons inside the mitochondrial respiratory chain and also acts as an antioxidant. High-dose oral CoQ10 (for example 5–30 mg/kg/day in divided doses) is widely used in mitochondrial disease “cocktails”, and primary CoQ10 deficiency clearly responds, though evidence in secondary OXPHOS defects is weaker. Side effects are usually mild (stomach upset, nausea). -
Riboflavin (vitamin B2)
Riboflavin is a precursor of FMN and FAD, which are cofactors in many OXPHOS enzymes. Doses like 50–400 mg/day in older children/adults (lower per-kg doses in infants) are used in mitochondrial disease. Riboflavin is generally safe; side effects can include yellow urine and mild stomach upset. It is “generally recognized as safe” and appears as an ingredient in several FDA-approved multivitamin products. -
Levocarnitine (L-carnitine)
L-carnitine helps transport long-chain fatty acids into mitochondria for β-oxidation and supports removal of toxic acyl groups. It is used in mitochondrial disease when carnitine deficiency is present or likely. Oral doses often range from 50–100 mg/kg/day in divided doses, under medical supervision. Levocarnitine injection (CARNITOR®) is FDA-approved for inborn errors causing secondary carnitine deficiency and for dialysis-related deficiency, not specifically for COXPD2. Side effects can include fishy body smell, diarrhea, and, rarely, seizures. -
L-arginine
L-arginine is a nitric-oxide precursor that may improve blood flow to energy-starved tissues. It is used off-label in some mitochondrial encephalopathies (especially MELAS) to treat or prevent stroke-like episodes, usually as IV infusion acutely and oral doses between episodes. Its benefit is still uncertain, and side effects can include low blood pressure, nausea, and electrolyte changes. -
Alpha-lipoic acid
Alpha-lipoic acid is an antioxidant cofactor inside mitochondria that helps enzymes in energy production and can scavenge free radicals. It is sometimes used as part of a cocktail (for example 10–20 mg/kg/day), though human data in mitochondrial disease are limited. Possible side effects include stomach upset and, rarely, low blood sugar in small children, so careful monitoring is needed. -
Thiamine (vitamin B1)
Thiamine is an essential cofactor for pyruvate dehydrogenase and other enzymes that link glycolysis to the Krebs cycle. In mitochondrial disease, doses higher than standard multivitamin levels may be tried (for example 50–300 mg/day depending on age) as part of a cocktail to support carbohydrate metabolism. It is usually well tolerated; very high doses can sometimes cause headache or nausea. -
Other B-complex vitamins (folate, niacin, B6, B12)
B-vitamins support many mitochondrial enzymes and DNA repair. Multivitamin infusions used in hospitals (such as M.V.I.-Adult and INFUVITE PEDIATRIC) contain combinations of these vitamins and are FDA-approved for parenteral nutrition, not specifically for mitochondrial disease. Side effects are uncommon but can include allergic reactions and, in some products, issues related to aluminum content. -
Antiseizure medicines (for example levetiracetam, others chosen by the neurologist)
Seizures are common in many mitochondrial diseases. Modern antiseizure drugs like levetiracetam are often preferred because they have fewer mitochondrial-toxic effects than some older drugs like valproic acid. Choice of drug, dose, and timing is highly individual. The main goal is good seizure control with the lowest effective dose and minimal side effects such as sleepiness or behavioral changes. -
Drugs to treat reflux and feeding problems (for example proton-pump inhibitors, prokinetics)
Severe reflux and vomiting can worsen poor growth and risk of aspiration. Proton-pump inhibitors (like omeprazole or lansoprazole) reduce stomach acid, while prokinetic drugs (chosen carefully) can help stomach emptying. These medications are not specific to mitochondrial disease but are often used to protect nutrition and lungs. -
Heart failure and rhythm medicines (in selected patients)
If heart involvement (cardiomyopathy or arrhythmia) is present, cardiologists may use standard heart medicines such as ACE inhibitors, beta-blockers, or diuretics. These drugs aim to reduce strain on the heart and improve pumping, using standard pediatric cardiology guidelines, not disease-specific data for MRPS16 deficiency. -
Experimental agents under study for mitochondrial disease
Research drugs such as omaveloxolone, bezafibrate, and others aim to increase mitochondrial biogenesis or improve NAD+ levels. These are usually available only in research trials and not as routine treatment. For MRPS16-COXPD2 specifically, there are no targeted trials yet, but families may be informed about registries and future studies. -
Idebenone (for certain mitochondrial diseases)
Idebenone is a synthetic analogue of CoQ10 that improves electron transfer and has antioxidant effects. It is approved in some countries for Leber hereditary optic neuropathy (LHON) and is being studied in other mitochondrial conditions. Doses like 5–20 mg/kg three times daily are used under specialist guidance. It is not specifically approved for MRPS16-COXPD2 but shows how targeting mitochondria can help in some related diseases.
(Again, there are not well-proven disease-specific drugs for MRPS16-COXPD2. The list above covers the main classes that have real supporting data in mitochondrial disorders.)
Dietary molecular supplements
These supplements are often part of a mitochondrial “cocktail”. Evidence varies, and they are not substitutes for medical care.
-
Coenzyme Q10 – described above; supports electron transport and acts as an antioxidant.
-
Riboflavin (B2) – supports flavin-dependent enzymes in the respiratory chain and fatty acid oxidation.
-
Thiamine (B1) – supports pyruvate dehydrogenase and α-ketoglutarate dehydrogenase, improving carbohydrate flow into the Krebs cycle.
-
L-carnitine – helps transport fatty acids into mitochondria for energy and removes toxic acyl groups as acyl-carnitines.
-
Alpha-lipoic acid – mitochondrial antioxidant and cofactor that may protect against oxidative damage and support enzyme activity.
-
Vitamin C and vitamin E – general antioxidants that can support defenses against free radicals generated by impaired OXPHOS.
-
Biotin – cofactor in carboxylase enzymes, sometimes included in cocktails though strong data in mitochondrial disease are limited.
-
Magnesium – important for ATP-related reactions and neuromuscular function; may be added if levels are low or for symptom relief such as cramps.
-
Taurine – an amino-acid derivative that may help mitochondrial function in some experimental models; sometimes combined with arginine in research for mitochondrial encephalopathy.
-
General high-quality multivitamin / trace elements – ensure no additional deficiencies (for example zinc, selenium) that could further weaken antioxidant and immune defenses.
Immune-supporting, regenerative and stem-cell-related approaches
There are no approved stem-cell or gene-therapy treatments yet for MRPS16-related COXPD2. Research is ongoing in mitochondrial replacement, gene therapy, and cell-based approaches, but these are still experimental.
Doctors may still use some drugs and strategies to support overall resilience:
-
Standard vaccination and infection control – immunizations and good hygiene indirectly support immunity and reduce infection-triggered crises.
-
Nutritional optimization – maintaining good protein, vitamins, and trace elements supports immune function and tissue repair.
-
Experimental regenerative or gene-based therapies (research only) – some trials in other mitochondrial diseases are exploring nucleoside supplementation, nuclear gene therapy, or mitochondrial replacement techniques, but these are not standard care and not specific to MRPS16 at this time.
Because there is no robust clinical evidence, I cannot honestly list six specific “immunity-booster stem-cell drugs” for this condition. Any future therapy here will almost certainly be delivered only inside specialized research centres.
Surgeries (procedures and why they are done)
There is no surgery that “fixes” the MRPS16 gene or cures combined oxidative phosphorylation deficiency. But some supportive procedures may be considered in severe cases:
-
Gastrostomy tube placement (G-tube)
A small opening is made into the stomach so feeds can be given directly through a tube. This is done when oral feeding is unsafe or too difficult because of swallowing problems, aspiration risk, or very slow feeding. It helps ensure steady nutrition and reduces hospital admissions for dehydration and poor weight gain. -
Fundoplication (reflux surgery)
The top part of the stomach is wrapped around the lower esophagus to reduce severe reflux. It may be done together with gastrostomy if reflux causes repeated aspiration pneumonia or severe discomfort despite medicines. -
Orthopedic surgery for contractures or hip dislocation
Children with severe muscle weakness and spasticity may develop joint contractures or hip dislocation. Orthopedic procedures to release tendons or stabilize hips can ease care, improve sitting comfort, and reduce pain, though they do not cure the underlying disease. -
Spinal surgery for severe scoliosis
If scoliosis becomes very severe and affects breathing or comfort, spinal fusion surgery may be considered by a specialized team. Risks must be weighed carefully in mitochondrial disease because of anesthetic risks and limited reserves. -
Tracheostomy (long-term airway access)
In rare cases of chronic respiratory failure or repeated severe airway obstruction, surgeons may create an opening in the neck into the windpipe (trachea) and place a tube. This allows long-term ventilation or easier suctioning but requires intensive home care.
Prevention and risk reduction
Because this condition is autosomal recessive, primary prevention focuses mainly on genetics:
-
Carrier testing and genetic counseling for parents – to understand recurrence risk.
-
Prenatal or pre-implantation genetic diagnosis in future pregnancies, when available.
For the affected child, we focus on reducing crises:
-
Avoid long fasting; use frequent feeds and sick-day plans.
-
Treat infections quickly and keep vaccinations up to date.
-
Avoid drugs known to be strongly mitochondrial-toxic when alternatives exist.
-
Maintain good hydration, especially during illness.
-
Avoid extreme heat, cold, or excessive physical stress.
-
Keep regular follow-ups with the metabolic/mitochondrial clinic.
-
Provide early developmental therapy to reduce secondary complications.
-
Plan surgeries and anesthesia only in centres experienced with mitochondrial disease, with careful pre-operative planning.
When to see a doctor urgently
For a child with combined oxidative phosphorylation deficiency, parents or caregivers should seek urgent medical help if there is:
-
Fast or laboured breathing, blue lips, or trouble breathing.
-
Fever, vomiting, or poor feeding that continues for more than a few hours.
-
New or worsening seizures, or unusual movements or staring spells.
-
Sudden change in alertness, such as being very sleepy, confused, or hard to wake.
-
Signs of dehydration (very few wet diapers, dry mouth, no tears).
-
Chest pain, very fast heart rate, or swelling of legs or face.
Regular (non-emergency) visits are also important to review growth, lab tests (such as lactate), heart and brain imaging, and support needs.
What to eat and what to avoid
Because strong data for a special “MRPS16 diet” do not exist, most experts suggest a balanced, age-appropriate diet with constant energy supply:
Generally encouraged (as tolerated, under dietitian guidance)
-
Frequent small meals with adequate calories and protein to avoid fasting.
-
Foods rich in complex carbohydrates (rice, oats, potatoes) to provide steady energy.
-
Healthy fats (olive oil, nut and seed oils if safe, avocado) for extra calories.
-
Plenty of fruits and vegetables to supply vitamins and antioxidants.
-
Adequate fluids to prevent dehydration.
Generally limited or avoided (especially in older children and adults)
-
Very long periods without food or “crash” diets.
-
Excessive simple sugars (very sugary drinks) that may worsen blood sugar swings.
-
Highly processed foods high in trans-fats and artificial additives.
-
Energy drinks, alcohol, and tobacco exposure in older adolescents/adults, which can stress mitochondria and the heart.
Diet should always be personalized by a metabolic dietitian, especially if there is lactic acidosis or other metabolic issues.
Frequently asked questions (FAQs)
-
Is combined oxidative phosphorylation deficiency caused by MRPS16 mutation curable?
Right now, there is no cure that fixes the MRPS16 gene or fully restores mitochondrial function. Treatment is supportive and focuses on making the child as stable and comfortable as possible, preventing crises, and supporting the family. Research in gene and mitochondrial therapies is growing, but nothing is yet approved for this specific condition. -
Are there any medicines approved exactly for this disease?
No medicine is officially approved just for “combined oxidative phosphorylation deficiency 2”. Some drugs and supplements (like CoQ10, riboflavin, levocarnitine, arginine) are used off-label based on experience with other mitochondrial disorders, but evidence is limited and they must be supervised by a specialist. -
What is a mitochondrial “cocktail”?
A mitochondrial cocktail is a mix of vitamins, cofactors, and antioxidants such as CoQ10, riboflavin, thiamine, L-carnitine, alpha-lipoic acid, and others. Doctors hope this combination will help mitochondrial enzymes work better and reduce oxidative stress, but strong proof of benefit in most mitochondrial diseases is still lacking. -
Can diet alone treat the disease?
Diet can support energy supply and prevent crises, but it cannot correct the genetic defect in MRPS16. Good nutrition is very important, but it works together with medical care, not instead of it. -
Is exercise safe in mitochondrial disease?
In older children and adults with milder disease, carefully supervised, low-to-moderate exercise can sometimes improve mitochondrial function. In severe neonatal conditions like MRPS16-COXPD2, activity is usually limited by weakness and medical instability, so physiotherapists focus on gentle movement and positioning, not strenuous exercise. -
Does CoQ10 really help?
CoQ10 clearly helps in primary CoQ10 deficiency and may help some other mitochondrial disorders, but not all. Studies show mixed results, and it is not a guaranteed treatment. However, it is relatively safe and widely used in mitochondrial practice. -
Is idebenone a treatment for this condition?
Idebenone is approved in some countries for a different mitochondrial disease (LHON) and supports electron transfer and antioxidant defenses. There is no specific evidence for MRPS16-COXPD2, so at present it would only be considered in research or special circumstances. -
Can L-arginine stop stroke-like episodes in mitochondrial disease?
In some types of mitochondrial disease such as MELAS, L-arginine is used during stroke-like episodes and sometimes between episodes, but the scientific evidence is mixed and not strong. For MRPS16-COXPD2, there is no specific data; any use would be based on general mitochondrial practice and must be guided by specialists. -
Is levocarnitine always needed?
Levocarnitine is mainly used when blood tests show low carnitine or when there is a strong risk of deficiency. Routine high-dose use without need may not help and can cause side effects. Doctors decide based on lab results and the overall metabolic picture. -
Can this condition affect the heart?
Many mitochondrial diseases can affect the heart muscle or rhythm. In MRPS16-COXPD2, serious brain and metabolic problems are usually more prominent, but heart monitoring (ECG, echocardiogram) is often done to detect any involvement early. -
What is lactic acidosis and why is it important?
Lactic acidosis means there is too much lactic acid in the blood. It happens when cells cannot make enough ATP through OXPHOS and switch to anaerobic metabolism. This can cause fast breathing, vomiting, and confusion, and is a key reason to treat illness early and avoid fasting. -
Will every baby with this mutation have the same severity?
Most reported cases of MRPS16-COXPD2 are severe, but the exact severity can vary depending on the specific mutations and possibly other genetic or environmental factors. Because the number of known patients is very small, predicting the exact course is difficult. -
Can parents or siblings be tested?
Yes. Genetic testing can identify carriers of MRPS16 mutations and can confirm whether siblings are affected, carriers, or unaffected. This helps with family planning and understanding risks for future generations. -
Is it safe to join research studies?
Clinical trials and registries can help improve knowledge and maybe give access to new treatments, but each study has risks and benefits. Families should discuss any research offer carefully with their medical team and make sure they understand what is involved. -
What is the most important message for families?
The disease is caused by a genetic change that parents did not choose and could not prevent. There is no simple cure now, but supportive care, early treatment of illness, good nutrition, and strong family and palliative support can make a real difference in comfort and quality of life. Staying linked with a specialist mitochondrial centre and genetic counseling services is essential.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: February 19, 2025.
